z-logo
open-access-imgOpen Access
What Constitutes a Valid Surrogate End Point in Cancer Clinical Trials?
Author(s) -
Yu Shyr,
Derek Shyr
Publication year - 2020
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2020.1847
Subject(s) - medicine , surrogate endpoint , endpoint determination , end point , cancer , medline , clinical trial , oncology , geometry , mathematics , political science , law

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom